on Onco-Innovations Limited (CVE:ONCO)
Onco-Innovations Achieves Key Milestone in ONC010 Manufacturing
Onco-Innovations Limited has announced a significant advancement in the production of the B4 precursor, which is crucial for developing their ONC010 Polynucleotide Kinase Phosphatase (PNKP) Inhibitor Technology. The kilogram-scale manufacturing was achieved in collaboration with Dalton Pharma Services, marking an important step in scaling the production process.
The successful production of approximately 952 grams of B4 underscores the scalability of Onco-Innovations' manufacturing strategy. This achievement supports the company's efforts to establish a reliable supply chain essential for the clinical development of ONC010. CEO Thomas O'Shaughnessy highlighted the progress, reinforcing the company's commitment to advancing toward clinical trials.
Additionally, Onco-Innovations has engaged InvestorBrandNetwork for market awareness services, with plans extending until September 2026. This step aims to enhance corporate communications and media presence, aligning with the company's broader clinical and regulatory objectives.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news